广济药业(000952) - 2019 Q4 - 年度财报

Financial Performance - The company's operating revenue for 2019 was CNY 731,340,517.94, a decrease of 13.33% compared to CNY 843,830,942.08 in 2018[16] - The net profit attributable to shareholders of the listed company was CNY 86,943,194.92, down 49.37% from CNY 171,728,909.16 in the previous year[16] - The net profit after deducting non-recurring gains and losses was CNY 51,022,090.01, a decline of 69.17% compared to CNY 165,485,071.01 in 2018[16] - The basic earnings per share decreased by 48.68% to CNY 0.350 from CNY 0.682 in 2018[16] - The weighted average return on equity was 9.48%, down 11.29% from 20.77% in the previous year[16] - Total assets at the end of 2019 were CNY 1,766,508,421.42, an increase of 4.32% from CNY 1,693,288,037.08 at the end of 2018[16] - The net assets attributable to shareholders of the listed company increased by 9.97% to CNY 960,377,290.08 from CNY 873,278,328.61 in 2018[16] - The net cash flow from operating activities was CNY 144,200,478.39, a decrease of 37.69% compared to CNY 231,438,796.44 in 2018[16] Dividend Distribution - The company plans to distribute a cash dividend of CNY 0.7 per 10 shares (including tax) and issue 2 bonus shares per 10 shares (including tax) based on a total of 286,666,616 shares[5] - The company plans to distribute a cash dividend of 0.7 yuan per 10 shares, totaling approximately 20,066,663.12 yuan (including tax) based on a total share capital of 251,705,513 shares as of December 31, 2019, resulting in a cash dividend ratio of 23.08%[85] - The company intends to issue 2 bonus shares for every 10 shares held, amounting to a total of 57,333,323 shares based on the same share capital[86] - The cash dividend for 2019 is based on a distributable profit of 525,180,665.59 RMB[92] - The company did not propose a cash dividend distribution plan for the year 2018, despite having a positive profit available for distribution[91] Research and Development - Research and development expenses decreased by 16.87% to 5,377.41 million yuan, primarily due to ongoing projects not meeting expense recognition conditions[37] - The company focused on enhancing its market competitiveness by optimizing the production process of core products, particularly VB2, and expanding production capacity for dosage forms[38] - The company is actively collaborating with research institutions to develop new products, enhancing its R&D capabilities[38] - The company authorized 2 invention patents and applied for 2 more, indicating a commitment to technological innovation[40] - The number of R&D personnel increased slightly by 0.51% from 195 in 2018 to 196 in 2019, while the proportion of R&D personnel to total staff decreased by 0.27%[55] Market and Sales Performance - Revenue from raw material products decreased by 22.35% to ¥554,483,216.99, while revenue from formulation products increased by 32.63% to ¥115,343,225.99[44] - Domestic revenue accounted for 63.87% of total revenue at ¥467,095,967.20, while international revenue decreased by 28.71% to ¥264,244,550.74, representing 36.13% of total revenue[44] - The company’s total sales volume in the pharmaceutical manufacturing sector was ¥709,727,144.03, a decline of 15.19% from ¥836,798,408.70 in 2018[47] - Sales expenses rose by 17.26% to ¥43,707,887.33 due to increased revenue from formulation products[54] Environmental Responsibility - The company has made significant investments in environmental protection facilities, demonstrating its commitment to sustainable development and social responsibility[30] - The company emphasizes environmental protection and has upgraded technology to improve energy efficiency and reduce emissions[127] - The company has established a wastewater treatment system that includes EGSB/A2O biochemical treatment, secondary sedimentation, and flotation systems[140] - The company has implemented air pollution control systems including bag dust removal, dual alkali desulfurization, and SNCR denitrification for boiler flue gas[140] - The company has a total of 1 direct emission outlet for sulfur dioxide with a discharge concentration of 55 mg/m³, which is within the standard limit of 400 mg/m³[138] Corporate Governance - The company has a solid governance structure, complying with relevant laws and regulations, ensuring no significant discrepancies with the requirements of the China Securities Regulatory Commission[186] - The company has established five specialized committees under the board, including the audit committee and the remuneration and assessment committee, to ensure effective governance[195] - Independent directors actively participated in board meetings, with attendance rates reflecting their commitment to governance[193] - The total remuneration paid to directors, supervisors, and senior management in 2019 amounted to 4.4332 million yuan[177] - The company has a diverse board with members holding various degrees and professional backgrounds, including finance and engineering[171] Social Contributions - The company donated a total of 200,000 CNY for rural construction and 10,000 CNY for educational support in 2019[128] - The company provided 1.65 million CNY to support 50 impoverished students as part of its educational poverty alleviation efforts[132] - The company actively participated in the fight against COVID-19, donating 1 million CNY to local government efforts and raising 257,264 CNY from employees[129] - The company has achieved a total of 4.5 million CNY in funds and 1.74 million CNY in material assistance for poverty alleviation efforts[132] - The company has helped 27 registered impoverished households to escape poverty through its initiatives[132]